EduardoDustyLunaMD

Endocrinology • Weslaco, TX

Diabetes, Lipid Metabolism, Osteoporosis & Bone Metabolism Medicine, Thyroid

Endocrinologist

Join to view full profile

Dr. Luna is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Luna's full profile

Already have an account?

Office
1116 E Eighth St
Suite #3
Weslaco, TX 78596
Phone+1 956-603-1555
Is this information wrong?

Education & Training

University of Texas Health Science Center San Antonio Joe and Teresa Lozano Long School of MedicineFellowship, Endocrinology, Diabetes, and Metabolism, 2016 - 2018
University of Texas Health Science Center San Antonio Joe and Teresa Lozano Long School of MedicineResidency, Internal Medicine, 2013 - 2016
University of Texas Health Science Center San Antonio Joe and Teresa Lozano Long School of MedicineInternship, Internal Medicine, 2013 - 2014
McGovern Medical School at UTHealthClass of 2013

Certifications & Licensure

TX State Medical License 2017 - 2024
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Endocrinology, Diabetes and Metabolism

Clinical Trials

A Study of Tirzepatide (LY3298176) on the Reduction on Morbidity and Mortality in Adults With Obesity Start of enrollment: 2022 Oct 11
Active, not recruiting
Phase 3
A Study of Daily Oral Orforglipron (LY3502970) Compared With Insulin Glargine in Participants With Type 2 Diabetes and Obesity or Overweight at Increased Cardiovascular Risk Start of enrollment: 2023 Apr 03
Recruiting
Phase 3
A Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes and Inadequate Glycemic Control With Insulin Glargine, With or Without Metformin and/or SGLT-2 Inhibitor Start of enrollment: 2023 Nov 10
Recruiting
Phase 3
A Donanemab (LY3002813) Prevention Study in Participants With Alzheimer's Disease (TRAILBLAZER-ALZ 3) Start of enrollment: 2021 Aug 27
Recruiting
Phase 3
A Study of Orforglipron (LY3502970) Compared With Semaglutide in Participants With Type 2 Diabetes Inadequately Controlled With Metformin Start of enrollment: 2023 Sep 22
Recruiting
Phase 3
Join now to see all

Press Mentions

Specialized Surgeons in Endocrinology Now Practicing in ValleyFebruary 20th, 2019

Professional Memberships

American College of Physicians - ACP
Member
American Association of Clinical Endocrinologists - AACE
Member
American Diabetes Association - ADA
Member
Endocrine Society
Member

Other Languages

Spanish

Hospital Affiliations

Doctor's Hospital at RenaissanceEdinburg, Texas
Knapp Medical CenterWeslaco, Texas
Rio Grande Regional HospitalMcAllen, Texas